CAN1012

About Canwell Pharma

CanWell Pharma is a clinical-stage oncology biotech developing a pipeline of novel ADCs and SMDCs through its proprietary StarLinker and SMDC platforms. Key assets include CAN016, a dual-payload HER2 ADC with an FDA-cleared IND, and CAN1012, a TLR7 agonist with Orphan Drug Designation for soft tissue sarcoma. The company operates with a dual US-China strategy, advancing multiple programs from preclinical to early clinical development to address resistance and toxicity challenges in cancer therapy.

Therapeutic Areas